Holen Sie sich die Stockscreener-App
57.95
0.62%
0.285
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Adagene Inc. Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - marketscreener.com
Adagene Receives Milestone Payment From Exelixis - marketscreener.com
Exelixis at Citigroup summit: building a second growth engine - Investing.com
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
A cancer-drug milestone brings Adagene a $2 million payment - Stock Titan
Transcript : Exelixis, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 11 - marketscreener.com
Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026) - JD Supra
Exelixis at Wells Fargo conference: zanzalintinib takes center stage By Investing.com - Investing.com Canada
Exelixis Stock Price Forecast. Should You Buy EXEL? - StockInvest.us
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Exelixis stock hits all-time high at 57.68 USD By Investing.com - Investing.com Australia
EXEL - Finviz
Exelixis stock hits all-time high at 57.68 USD - Investing.com
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2026 - BioSpace
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire
Exelixis secures Cabometyx exclusivity with patent win - BioWorld News
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data - Seeking Alpha
Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win - Law360
Exelixis wins appeals court ruling upholding key patents, FDA approval barred until at least Jan 15, 2030 - TradingView
Exelixis Wins Appeal in Patent Case Against MSN Laboratories - marketscreener.com
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win - GuruFocus
Exelixis Says U.S. Court Of Appeals For Federal Circuit Affirms Key Portion Of 2024 Judgment In Co's Favor - TradingView
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories - Business Wire
Exelixis Preserves Win Over MSN on Cabometyx Cancer Drug Patents - Bloomberg Law News
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Through Biotechnology with High Return on Equity - DirectorsTalk Interviews
Strong Sales, Earnings Send Exelixis Shares Higher - Yahoo Finance
Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition - Trefis
Here's Why Exelixis (EXEL) is a Strong Value Stock - Eastern Progress
NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL - MarketBeat
51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC - MarketBeat
BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL - MarketBeat
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law - The Daily Tribune News
FARALLON CAPITAL MANAGEMENT, L.L.C. Buys More Exelixis Inc (EXEL - GuruFocus
BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" - MarketBeat
Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXEL - MarketBeat
Out of sight, out of work? What’s driving remote job cuts - BioSpace
Investigation launched into EXELIXIS officers f... - Pluang
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - PR Newswire
Exelixis Inc : BMO Initiates Coverage With Ma - Moomoo
EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54 - Bitget
BMO initiates Exelixis stock at Market Perform, cites patent cliff By Investing.com - Investing.com Australia
EXEL Initiates Coverage On BMO Capital -- Price Target Announced at $54.00 - GuruFocus
BMO initiates Exelixis stock at Market Perform, cites patent cliff - Investing.com
JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL - MarketBeat
AQR Capital Management Trims Exelixis Inc (EXEL) Stake -- Shares Trade 16% Above GF Value - GuruFocus
EXEL Looks 16.3% Overvalued on GF Value™ - GuruFocus
Pallas Capital Advisors LLC Invests $1.67 Million in Exelixis, Inc. $EXEL - MarketBeat
27,109 Shares in Exelixis, Inc. $EXEL Purchased by Grandfield & Dodd LLC - MarketBeat
Exelixis (EXEL) Climbs 2.48% as Shares Test Key Resistance at $55.14ATR Stop - vinanet.vn
Exelixis (EXEL) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating the 3.31% Upside with Strong Revenue Growth - DirectorsTalk Interviews
Focus Partners Advisor Solutions LLC Buys Shares of 26,603 Exelixis, Inc. $EXEL - MarketBeat
Exelixis (MIC:EXEL-RM) EV-to-OCF : 0.00 (As of Aug. 16, 2026) - GuruFocus
Exelixis (EXEL) Is Down 5.2% After Raising Q2 Profitability And Trimming 2026 Revenue Outlook – Has The Bull Case Changed? - Sahm
EXEL|Exelixis Inc|Price:50.990| - TradingKey
Farallon Capital (EXEL) discloses 13.99M-share Exelixis stake at $308M cost - Stock Titan
EXEL|Exelixis Inc|Price:52.360|Chg%:+1.120 - TradingKey
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL) - GlobeNewswire
Exelixis Inc (EXEL) Director Mary Beckerle Sells 9,812 Shares - GuruFocus
Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada
Exelixis director Mary Beckerle sells $526k in shares - Investing.com
Exelixis director Mary Beckerle sells $526k in shares By Investing.com - Investing.com South Africa
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):